Brought to you by 
Lorus acquires GeneSense in stock deal
20 Apr 2000
Executive Summary
Lorus Therapeutics will acquire privately held GeneSense Technologies (antisense cancer drugs) in an all-stock transaction, with the goal of creating Canada's leading cancer biopharmaceutical company.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lorus acquires GeneSense in stock deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice